INSULET CORPORATION
Insulet Corporation (PODD) is a medical‑device company best known for its Omnipod tubeless insulin pump system, aimed at people with type 1 and insulin‑dependent type 2 diabetes. The business model centres on device sales and recurring pod consumables, with supplementary software and services that support automated insulin delivery. With a market capitalisation of roughly $23.2 billion, growth prospects hinge on rising adoption of insulin‑delivery technology, tighter integration with continuous glucose monitoring and expansion into international markets. Key investor considerations include manufacturing scale‑up, reimbursement and regulatory pathways, competition from established pump makers and integrated diabetes platforms, and execution risk around new product roll‑outs. Financial performance can be variable and past performance is not a guarantee of future returns. This is general educational information only and not personal advice; investors should assess suitability for their own circumstances and may wish to consult a regulated financial adviser.
Why It's Moving
PODD Faces Mixed Signals as Analysts Rally Behind Strong Buy Consensus Despite Fresh Downgrade
- Rothschild & Co downgraded PODD on April 24, slashing the price target to $220, signaling caution on near-term execution risks in a competitive landscape.
- Majority of 37 analysts maintain Buy or Strong Buy ratings, highlighting Insulet's leadership in tubeless insulin delivery systems driving patient adoption.
- Consensus points to PODD's superior ROA forecast of 28.33% versus the medical devices industry average of 15.1%, underscoring operational strength.
PODD Faces Mixed Signals as Analysts Rally Behind Strong Buy Consensus Despite Fresh Downgrade
- Rothschild & Co downgraded PODD on April 24, slashing the price target to $220, signaling caution on near-term execution risks in a competitive landscape.
- Majority of 37 analysts maintain Buy or Strong Buy ratings, highlighting Insulet's leadership in tubeless insulin delivery systems driving patient adoption.
- Consensus points to PODD's superior ROA forecast of 28.33% versus the medical devices industry average of 15.1%, underscoring operational strength.
When is the next earnings date for INSULET CORPORATION (PODD)?
Insulet Corporation (PODD) is scheduled to report its next earnings on May 6, 2026, before market open. This release will cover the first quarter of 2026 (Q1 2026), following the prior report on February 18, 2026, for Q4 2025. Investors should monitor for the associated conference call, typically held shortly after the release. Note that one source projects April 30, but the consensus points to early May based on recent patterns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Insulet Corporation's stock, with a target price of $380.13, indicating significant growth potential.
Financial Health
Insulet Corporation is performing well with strong revenue and profitability, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring PODD
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth from Adoption
Increasing uptake of insulin‑delivery technology could drive revenue through devices and recurring pods, though adoption rates and reimbursement vary by market.
International Expansion
Rolling out into new regions offers scale potential, balanced against regulatory approvals, local reimbursement and distribution challenges.
Innovation & Partnerships
Integration with continuous glucose monitors and progress toward automated insulin delivery can be strategic catalysts, yet execution and competition are material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.